StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen AMJEVITA / AMGEVITA (adalimumab-atto by Quarter

AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

Amgen AMJEVITA / AMGEVITA (adalimumab-atto: $155M in Q2 2026, up 16.5% from a year earlier.

Latest, Q2 2026
155
Period ended Jun 30, 2026
Change on a year earlier
+16.5%
133 in Q2 2025
History
31 quarters
Since Q4 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| AMJEVITA ® /AMGEVITA ™ | 26 | 129 | 155 | 133 | 17%”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026155+16.5%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026173+27.2%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025174-40.8%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025154-7.2%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20251330.0%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025136-19.0%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 2024294+83.7%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024166+9.2%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024133-11.3%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024168+2.4%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023160+34.5%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023152+29.9%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023150+29.3%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023164+51.9%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022119+3.5%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022117+5.4%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up AMJEVITA / AMGEVITA (adalimumab-atto

Cite this data

StockData. (2026). Amgen AMJEVITA / AMGEVITA (adalimumab-atto ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-amjevita-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.